Intestinal Current Measurements (ICM) to Evaluate the Activation of Mutant CFTR in Subjects With Cystic Fibrosis Aged 12 Years and Older, Homozygous for the p.Phe508del-CFTR Mutation, Treated With Lumacaftor in Combination With Ivacaftor
Phase of Trial: Phase IV
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Biomarker; Pharmacodynamics
- Acronyms OrkambiFacts
- 26 Feb 2018 Planned number of patients changed from 125 to 100.
- 12 Jan 2018 Results (n=53; till March 2017) assessing effect of lumacaftor -ivacaftor on biomarkers published in the American Journal of Respiratory and Critical Care Medicine.
- 10 Jun 2017 Biomarkers information updated